Haizheng Pharmaceutical's directional convertible bonds listed and transferred on June 30, 2022 are referred to as "Haizhengduan" for short, and its company is one of the largest production bases of antibiotics and anti-tumor drugs in China.
Haizhi refers to Zhejiang Haizheng Pharmaceutical Co., Ltd., which was established in 1956 and located in Taizhou, Zhejiang, a port city in the southeast coast of China. At present, Haizheng has become a leading manufacturer of APIs in China and one of the largest production bases of antibiotics and antineoplastic drugs in China.